Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.

Malignant melanoma

Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or ugly looking.. Thinking of ABCDE can help you remember what to watch for:: - Asymmetry - the shape of one half does not match the other. - Border - the edges are ragged, blurred or irregular. - Color - the color is uneven and may include shades of black, brown and tan. - Diameter - there is a change in size, usually an increase. -Evolving - the mole has changed over the past few weeks or months. Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
9944
Concept ID:
C0025202
Neoplastic Process
2.

Melanoma

The presence of a `melanoma` (MPATH:359), a malignant cancer originating from pigment producing melanocytes. Melanoma can originate from the skin or the pigmented layers of the eye (the uvea). [from HPO]

MedGen UID:
505377
Concept ID:
CN002586
Finding
3.

Metastatic melanoma

A melanoma that has spread from its primary site to another anatomic site. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004 [from NCI]

MedGen UID:
83002
Concept ID:
C0278883
Neoplastic Process
4.

MART-1 Antigen

A tumor-associated melanocytic differentiation antigen. Vaccination with MART-1 antigen may stimulate a host cytotoxic T-cell response against tumor cells expressing the melanocytic differentiation antigen, resulting in tumor cell lysis. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42205&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42205&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C28724" NCI Thesaurus) [from PDQ]

MedGen UID:
282724
Concept ID:
C1522481
Pharmacologic Substance
5.

Hypophysitis

MedGen UID:
575012
Concept ID:
C0342409
Disease or Syndrome
6.

tremelimumab

A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition. [from NCI]

MedGen UID:
379354
Concept ID:
C2351038
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...